Edition:
United States

Allergan plc (AGN)

AGN on New York Consolidated

214.58USD
19 Jan 2017
Change (% chg)

$-1.98 (-0.91%)
Prev Close
$216.56
Open
$217.00
Day's High
$217.46
Day's Low
$214.15
Volume
3,142,654
Avg. Vol
4,720,585
52-wk High
$301.98
52-wk Low
$184.50

Latest Key Developments (Source: Significant Developments)

Allergan announces FDA approval of RHOFADE cream
7:59am EST 

Allergan Plc : Allergan announces FDA approval of RHOFADE™ (oxymetazoline hydrochloride) cream, 1% for the topical treatment of persistent facial Erythema associated with Rosacea in adults .Allergan Plc - RHOFADE will be available for commercial supply starting may 2017 in United States.  Full Article

Allergan enters parkinson's disease through option arrangement with Lysosomal Therapeutics
Monday, 9 Jan 2017 08:30am EST 

Allergan Plc : Allergan enters parkinson's disease through option arrangement with Lysosomal Therapeutics Inc (LTI) for its potential first-in-class breakthrough compounds . Allergan Plc - additional terms were not disclosed. . Allergan Plc - purchased an option right directly from LTI shareholders to acquire LTI following completion of a phase 1b trial for LTI-291 . Allergan Plc - option to acquire LTI following completion of phase 1B clinical trial . Allergan Plc - Allergan will provide a separate upfront research and development payment .Allergan Plc - Allergan and LTI will establish a joint development committee to oversee development activities for LTI-291.  Full Article

Allergan enters into licensing agreement with Assembly Biosciences
Monday, 9 Jan 2017 08:00am EST 

Allergan Plc : Will make upfront payment to assembly of $50 million for exclusive, worldwide rights to develop and commercialize UC, CD and IBS compounds . Assembly will be entitled to receive success-based development and commercial milestone payments . Assembly is also eligible to receive tiered royalties based on net sales . Co, Assembly will share development costs through proof-of-concept (POC) studies, and Allergan will assume all post-POC development costs .Allergan enters into licensing agreement with Assembly Biosciences to obtain worldwide rights to microbiome gastrointestinal development programs.  Full Article

Allergan CEO says will not take second price increase in June
Thursday, 5 Jan 2017 11:00am EST 

Allergan Plc - : Allergan CEO says proper guidance will come in a few weeks; but we've said Restasis net revenue will stay flat, "I think that's conservative" . Allergan CEO: "It seems the industry is taking pricing seriously...I'm encouraged by what I've seen in January so far" . Allergan CEO: "let's see what happens in June, we will not be taking a second increase in June" . Allergan CEO says we would like to see even stronger growth internationally, and think that's possible . Allergan CEO says in terms of data & submissions 2018 is a bigger year than 2017 . Allergan CEO: "its completely within the control of the industry", when asked about incoming Trump administration and its plans . Allergan CEO: "we're not asking people not to take price increases, but to be thoughtful of their price increases" Further company coverage: [AGN.N] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Allergan says about 40.5 mln shares worth $8 bln were received, retired during Nov. 2016
Friday, 2 Dec 2016 07:44am EST 

Allergan Plc : Allergan provides update on accelerated share repurchase (ASR) program . Allergan Plc - approximately 40.5 million shares worth $8 billion were received and retired by Allergan during November 2016 .Allergan Plc - remaining shares, if any, under ASR will be received and retired by Q3 of 2017.  Full Article

Allergan completes acquisition of Chase Pharmaceuticals
Tuesday, 22 Nov 2016 04:15pm EST 

Allergan Plc : Allergan acquires Chase Pharmaceuticals to expand CNS research and development pipeline and build on commitment to alzheimer's disease . Deal for an upfront payment of $125 million . Allergan to advance CPC-201 into Phase 3 registration study in 2017 . Deal includes additional potential milestone payments related to chase's lead compound, CPC-201, and certain backup compounds .Allergan plc - Allergan to advance cpc-201 into phase 3 registration study in 2017.  Full Article

Allergan receives FDA clearance for a new surgical treatment for refractory glaucoma
Tuesday, 22 Nov 2016 07:35am EST 

Allergan Plc : Allergan receives FDA clearance for the xen® gel stent, a new surgical treatment for refractory glaucoma . Allergan Plc - Allergan plans to launch xen in U.S. In early 2017 .Allergan Plc - Allergan plans to launch xen glaucoma treatment system in U.S. in early 2017.  Full Article

Allergan received an additional approval from Health Canada for fibristal
Monday, 21 Nov 2016 08:00am EST 

Allergan Plc :Allergan Plc - received an additional approval from Health Canada for fibristal.  Full Article

Urogen Pharma announces agreement to license RTGEL for use with Neurotoxins to Allergan
Friday, 14 Oct 2016 07:00am EDT 

Allergan Plc : Press release - Urogen Pharma announces agreement to license RTGEL™ for use with Neurotoxins to Allergan .Urogen Pharma - Allergan to make upfront payment of $17.5 million, as well as potential development and commercial milestones and royalties on net sales.  Full Article

Allergan says FDA accepts supplemental new drug application for avycaz
Tuesday, 11 Oct 2016 08:01am EDT 

Allergan Plc: FDA accepts supplemental new drug application (SNDA) for avycaz® (ceftazidime and avibactam) . Allergan plc - FDA is expected to take action on filing in q1 of 2017. . Allergan - application seeks to expand avycaz label to include phase 3 clinical data for treatment of complicated urinary tract infections .Allergan plc - application included results from a phase 3 study evaluating efficacy and safety of avycaz for treatment of patients with cuti.  Full Article

BRIEF-Allergan announces FDA approval of RHOFADE cream

* Allergan announces FDA approval of RHOFADE (oxymetazoline hydrochloride) cream, 1% for the topical treatment of persistent facial Erythema associated with Rosacea in adults